(a)
Study— The Comptroller General of the United States shall conduct a study on—
(1)
the efficacy of Federal drug surveillance systems in providing up-to-date information on illicit drug use in the United States, including any limitations affecting such efficacy; and
(2)
how such systems are used to address illicit drug use in the United States.
(b)
Report— Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall complete the study under subsection (a) and submit to Congress a report containing—
(1)
the findings and conclusions of such study; and
(2)
any recommendations for legislative or administrative actions to improve the efficacy of the Federal drug surveillance systems examined in such study, including any recommendations pertaining to interagency communication or data collection procedures.
(c)
Federal drug surveillance systems defined— In this section, the term Federal drug surveillance systems includes—
(1)
the Drug Overdose Surveillance and Epidemiology System of the Centers for Disease Control and Prevention (commonly known as “DOSE”);
(2)
the State Unintentional Drug Overdose Reporting System of the Centers for Disease Control and Prevention (commonly known as “SUDORS”);
(3)
the National Drug Early Warning System of the National Institute on Drug Abuse (commonly known as “NDEWS”); and
(4)
the Drug Abuse Warning Network of the Substance Abuse and Mental Health Services Administration (commonly known as “DAWN”).